Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Reports Increased Revenues in Q4

NEW YORK, Jan. 28 (GenomeWeb News) – PerkinElmer today reported revenues of $432.6 million for the fourth quarter ended Dec. 28, 2003, up from $410 million for the same period in 2002.

The increase, which included a 6 percent boost from foreign currency exchange rate fluctuations, was driven by revenue growth in all segments, the company said in a statement.

The company had net income of $28 million for the quarter, compared to a loss of $2.6 million for the year-ago quarter. The company had net income of $52 million for the year, compared to a loss of $152 million for 2002.

PerkinElmer had research and development expenditures of $20 million for the fourth quarter, compared to $22 million for the year-ago period.

Cash and cash equivalents on hand at the end of the quarter totaled $191 million, compared to $131 million for the same period in 2002.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.